UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | August 30, 2011 | |
| | Date of Report (Date of earliest event reported) | |
| | BIONOVO, INC. | |
| | (Exact Name of Registrant as Specified in Charter) | |
| Delaware | | 001-33498 | | 20-5526892 |
| (State or Other | | (Commission File Number) | | (IRS Employer |
| Jurisdiction of Incorporation) | | | | Identification No.) |
| 5858 Horton Street, Suite 400, Emeryville, CA 94608 |
| (Address of Principal Executive Offices) (Zip Code) |
| (510) 601-2000 |
| (Registrant's telephone number, including area code) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
On August 30, 2011, Bionovo, Inc. (the “Company”) issued a press release announcing positive results from the completion of the Company’s tolerability trial of MenerbaTM (MF101) for menopausal hot flashes. A copy of this press release is furnished as Exhibit 99.1 to this Current Report.
| Item 9.01. | Financial Statements and Exhibits. |
| | Exhibit | | |
| | Number | | |
| | | | |
| | 99.1 | | Press Release, dated August 30, 2011, titled “Bionovo Announces Positive Results of the Tolerability Trial of Menerba (MF101) for Menopausal Hot Flashes” |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | Bionovo, Inc. |
| | | |
| Date: August 30, 2011 | By: | /s/ Isaac Cohen |
| | | Isaac Cohen |
| | | Chairman and Chief Executive Officer |
EXHIBIT INDEX
| 99.1 | | Press Release, dated August 30, 2011, titled “Bionovo Announces Positive Results of the Tolerability Trial of Menerba (MF101) for Menopausal Hot Flashes” |
